{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:39:40Z","timestamp":1784327980742,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Science Fund for Distinguished Young Scholars","award":["82404762"],"award-info":[{"award-number":["82404762"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-01035-6","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:58:57Z","timestamp":1763463537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Revised therapeutic window for vancomycin in pediatric patients: evidence from a retrospective therapeutic drug monitoring study"],"prefix":"10.1186","volume":"26","author":[{"given":"Tao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasa","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"5","key":"1035_CR1","doi-asserted-by":"publisher","first-page":"e882","DOI":"10.1093\/infdis\/jiaf059","volume":"231","author":"S Schouwenburg","year":"2025","unstructured":"Schouwenburg S, Preijers T, Flint RB, Wildschut ED, Koch BCP, de Winter BCM, et al. Prediction of Vancomycin Area-under-the-curve using trough concentrations only: performance evaluation of pediatric population Pharmacokinetic models. J Infect Dis. 2025;231(5):e882\u201390.","journal-title":"J Infect Dis"},{"issue":"11","key":"1035_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of Vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American society of Health-System pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"1035_CR3","first-page":"406","volume":"22","author":"RS Pettit","year":"2017","unstructured":"Pettit RS, Peters SJ, McDade EJ, Kreilein K, Patel R, Epps K, et al. Vancomycin dosing and monitoring in the treatment of cystic fibrosis: results of a National practice survey. J Pediatr Pharmacol Ther. 2017;22(6):406\u201311.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"1035_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the American society of Health-System pharmacists, and the society of infectious diseases pharmacists. Clin Infect Dis. 2009;49(3):325\u20137.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1035_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1097\/INF.0000000000004415","volume":"43","author":"L Ashkenazi-Hoffnung","year":"2024","unstructured":"Ashkenazi-Hoffnung L, Schiller O, Krubiner M, Dagan O, Haskin O, Manor-Shulman O, et al. Vancomycin dosing and its association with acute kidney injury in pediatric cardiac intensive care patients under 3 months of age. Pediatr Infect Dis J. 2024;43(10):963\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"1035_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/bcpt.13303","volume":"126","author":"T Zhang","year":"2020","unstructured":"Zhang T, Cheng H, Pan Z, Mi J, Dong Y, Zhang Y, et al. Desired Vancomycin trough concentration to achieve an AUC(0\u201324)\/MIC\u2009>\u2009=\u2009400 in Chinese children with complicated infectious diseases. Basic Clin Pharmacol Toxicol. 2020;126(1):75\u201385.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"1035_CR7","doi-asserted-by":"publisher","first-page":"e0162422","DOI":"10.1128\/aac.01624-22","volume":"67","author":"M Lv","year":"2023","unstructured":"Lv M, Yang P, Zhang S, Wang L, Sun K, Zhao L. Population pharmacokinetics and dosage optimization of Vancomycin in pediatric patients with skin and soft tissue infections, Bone, and joint infections. Antimicrob Agents Chemother. 2023;67(1):e0162422.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1035_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of Methicillin-Resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285\u201392.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1035_CR9","first-page":"430","volume":"28","author":"WXS Lim","year":"2023","unstructured":"Lim WXS, Seah XFV, Thoon KC, Han Z. Comparison of Vancomycin Trough-Based and 24-Hour area under the curve over minimum inhibitory concentration (AUC\/MIC)-Based therapeutic drug monitoring in pediatric patients. J Pediatr Pharmacol Ther. 2023;28(5):430\u20138.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"1035_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s11096-024-01745-7","volume":"46","author":"M Yin","year":"2024","unstructured":"Yin M, Jiang Y, Yuan Y, Li C, Gao Q, Lu H, et al. Optimizing Vancomycin dosing in pediatrics: a machine learning approach to predict trough concentrations in children under four years of age. Int J Clin Pharm. 2024;46(5):1134\u201342.","journal-title":"Int J Clin Pharm"},{"issue":"11","key":"1035_CR11","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1111\/bcp.14084","volume":"85","author":"N Sosnin","year":"2019","unstructured":"Sosnin N, Curtis N, Cranswick N, Chiletti R, Gwee A. Vancomycin is commonly under-dosed in critically ill children and neonates. Br J Clin Pharmacol. 2019;85(11):2591\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1035_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2174\/1573396318666220307115307","volume":"18","author":"HM Tuan","year":"2022","unstructured":"Tuan HM, Anh NT, Quan KT, Thang NV, Huy VQ. Effect of initial Vancomycin dose and creatinine clearance on the attainment of target trough concentration in children. Curr Pediatr Rev. 2022;18(4):318\u201325.","journal-title":"Curr Pediatr Rev"},{"issue":"6","key":"1035_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/PCC.0000000000002918","volume":"23","author":"PT Scully","year":"2022","unstructured":"Scully PT, Lam WM, Coronado Munoz AJ, Modem VM. Augmented renal clearance of Vancomycin in suspected sepsis: Single-Center, retrospective pediatric cohort. Pediatr Crit Care Med. 2022;23(6):444\u201352.","journal-title":"Pediatr Crit Care Med"},{"key":"1035_CR14","doi-asserted-by":"publisher","unstructured":"Zhang T, Yi J, Cheng H, Han X, Wang Y, Xie J et al. Therapeutic drug monitoring of vancomycin in pediatric patients: a retrospective study. https:\/\/doi.org\/10.21203\/rs.3.rs-7050678\/v1","DOI":"10.21203\/rs.3.rs-7050678\/v1"},{"issue":"3","key":"1035_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/jcpt.12806","volume":"44","author":"T Zhang","year":"2019","unstructured":"Zhang T, Cheng H, Li Y, Dong YZ, Zhang Y, Cheng XL, et al. Paediatric acute kidney injury induced by Vancomycin monotherapy versus combined Vancomycin and meropenem. J Clin Pharm Ther. 2019;44(3):440\u20136.","journal-title":"J Clin Pharm Ther"},{"issue":"10474","key":"1035_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(24)02385-7","volume":"405","author":"M Ostermann","year":"2025","unstructured":"Ostermann M, Lumlertgul N, Jeong R, See E, Joannidis M, James M. Acute kidney injury. Lancet. 2025;405(10474):241\u201356.","journal-title":"Lancet"},{"issue":"8","key":"1035_CR17","doi-asserted-by":"publisher","first-page":"e0013822","DOI":"10.1128\/aac.00138-22","volume":"66","author":"L Cao","year":"2022","unstructured":"Cao L, Li Z, Zhang P, Yong S. Relationship between Vancomycin trough serum concentrations and clinical outcomes in children: a systematic review and Meta-Analysis. Antimicrob Agents Chemother. 2022;66(8):e0013822.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1035_CR18","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/psp4.13151","volume":"13","author":"X Shen","year":"2024","unstructured":"Shen X, Li X, Lu J, Zhu J, He Y, Zhang Z, et al. Population Pharmacokinetic analysis for dose regimen optimization of Vancomycin in Southern Chinese children. CPT Pharmacometrics Syst Pharmacol. 2024;13(7):1201\u201313.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"1035_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/phar.2617","volume":"41","author":"DH Rhoney","year":"2021","unstructured":"Rhoney DH, Metzger SA, Nelson NR. Scoping review of augmented renal clearance in critically ill pediatric patients. Pharmacotherapy. 2021;41(10):851\u201363.","journal-title":"Pharmacotherapy"},{"key":"1035_CR20","doi-asserted-by":"publisher","first-page":"648668","DOI":"10.3389\/fphar.2021.648668","volume":"12","author":"K Shen","year":"2021","unstructured":"Shen K, Fan Y, Yang M, Chen Y, Tao J, Lu G, et al. Modeling approach to optimizing dose regimen of Vancomycin for Chinese pediatric patients with Gram-Positive bacterial infections. Front Pharmacol. 2021;12:648668.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1035_CR21","doi-asserted-by":"publisher","first-page":"106515","DOI":"10.1016\/j.ijantimicag.2021.106515","volume":"59","author":"D Alrahahleh","year":"2022","unstructured":"Alrahahleh D, Xu S, Luig M, Kim HY, Alffenaar JW. Dosing of Vancomycin and target attainment in neonates: a systematic review. Int J Antimicrob Agents. 2022;59(2):106515.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1035_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1542\/hpeds.2014-0019","volume":"4","author":"LM Geerlof","year":"2014","unstructured":"Geerlof LM, Boucher J. Evaluation of Vancomycin dosing and corresponding drug concentrations in pediatric patients. Hosp Pediatr. 2014;4(6):342\u20137.","journal-title":"Hosp Pediatr"},{"issue":"5","key":"1035_CR23","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1007\/s11096-021-01266-7","volume":"43","author":"T Van Der Heggen","year":"2021","unstructured":"Van Der Heggen T, Buyle FM, Claus B, Somers A, Schelstraete P, De Paepe P, et al. Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life. Int J Clin Pharm. 2021;43(5):1394\u2013403.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"1035_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1542\/hpeds.2014-0081","volume":"5","author":"SH Durham","year":"2015","unstructured":"Durham SH, Simmons ML, Mulherin DW, Foland JA. An evaluation of Vancomycin dosing for complicated infections in pediatric patients. Hosp Pediatr. 2015;5(5):276\u201381.","journal-title":"Hosp Pediatr"},{"key":"1035_CR25","doi-asserted-by":"crossref","unstructured":"Eiland LS, English TM, Eiland EH 3. Assessment of Vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45(5):582\u20139.","DOI":"10.1345\/aph.1P588"},{"issue":"11","key":"1035_CR26","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","volume":"29","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Therapeutic monitoring of Vancomycin in adults summary of consensus recommendations from the American society of Health-System pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Pharmacotherapy. 2009;29(11):1275\u20139.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"1035_CR27","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/INF.0000000000001882","volume":"37","author":"TM Fiorito","year":"2018","unstructured":"Fiorito TM, Luther MK, Dennehy PH, LaPlante KL, Matson KL. Nephrotoxicity with Vancomycin in the pediatric population: A systematic review and Meta-Analysis. Pediatr Infect Dis J. 2018;37(7):654\u201361.","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 4","key":"1035_CR28","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/cid\/ciaa1536","volume":"71","author":"N He","year":"2020","unstructured":"He N, Su S, Ye Z, Du G, He B, Li D, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese Pharmacological society. Clin Infect Dis. 2020;71(Suppl 4):S363\u201371.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1035_CR29","doi-asserted-by":"publisher","first-page":"e0028321","DOI":"10.1128\/Spectrum.00283-21","volume":"9","author":"P Fu","year":"2021","unstructured":"Fu P, Xu H, Jing C, Deng J, Wang H, Hua C, et al. Bacterial epidemiology and antimicrobial resistance profiles in children reported by the ISPED program in China, 2016 to 2020. Microbiol Spectr. 2021;9(3):e0028321.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"1035_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13052-022-01262-1","volume":"48","author":"A La Vecchia","year":"2022","unstructured":"La Vecchia A, Ippolito G, Taccani V, Gatti E, Bono P, Bettocchi S, et al. Epidemiology and antimicrobial susceptibility of Staphylococcus aureus in children in a tertiary care pediatric hospital in Milan, Italy, 2017\u20132021. Ital J Pediatr. 2022;48(1):67.","journal-title":"Ital J Pediatr"},{"issue":"7","key":"1035_CR31","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.12669\/pjms.36.7.3273","volume":"36","author":"F Arshad","year":"2020","unstructured":"Arshad F, Saleem S, Jahan S, Tahir R. Assessment of Vancomycin MIC creep phenomenon in Methicillin-Resistant Staphylococcus aureus isolates in a tertiary care hospital of Lahore. Pak J Med Sci. 2020;36(7):1505\u201310.","journal-title":"Pak J Med Sci"},{"issue":"10","key":"1035_CR32","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jiph.2020.07.008","volume":"13","author":"S Aljohani","year":"2020","unstructured":"Aljohani S, Layqah L, Masuadi E, Al Alwan B, Baharoon W, Gramish J, et al. Occurrence of Vancomycin MIC creep in methicillin resistant isolates in Saudi Arabia. J Infect Public Health. 2020;13(10):1576\u20139.","journal-title":"J Infect Public Health"},{"issue":"1","key":"1035_CR33","doi-asserted-by":"publisher","first-page":"077","DOI":"10.1093\/tropej\/fmaa077","volume":"67","author":"C Wang","year":"2021","unstructured":"Wang C, Hao W, Yu R, Wang X, Zhang J, Wang B. Analysis of pathogen distribution and its antimicrobial resistance in bloodstream infections in hospitalized children in East China, 2015\u20132018. J Trop Pediatr. 2021;67(1):077.","journal-title":"J Trop Pediatr"},{"issue":"2","key":"1035_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/jpids\/pit076","volume":"3","author":"CA Knoderer","year":"2014","unstructured":"Knoderer CA, Nichols KR, Lyon KC, Veverka MM, Wilson AC. Are elevated Vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children? J Pediatr Infect Dis Soc. 2014;3(2):127\u201331.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"1035_CR35","doi-asserted-by":"crossref","unstructured":"Lee Y, Kim G, Lee J, Optimal Vancomycin AUC. Target in pediatric MRSA bacteremia: a Bayesian-guided approach. Pediatr Infect Dis J. 2025;44(10):942\u20138.","DOI":"10.1097\/INF.0000000000004841"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01035-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T23:05:22Z","timestamp":1763507122000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-01035-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01035-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7050678\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations (including the Helsinki Declaration). All experimental protocols were approved by the Institutional Review Board (IRB) of the Stomatology College Affiliated to Xi\u2019an Jiaotong University (Approval No.: 2024-XJKQIEC-KY-QT-0050-001). The requirement for informed consent was waived by the same IRB due to the retrospective nature of the study and the use of anonymized clinical data, in compliance with local regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}